Precise profiling. Expert analysis. Complete results.
NeoGenomics is proud to announce a new NGS-only assay for
the assessment of heme cancers. Neo Comprehensive™ – Heme Cancers is now
Comprehensive – Heme Cancers is a DNA & RNA next-generation
sequencing (NGS) comprehensive genomic profile (CGP) that analyzes 433 genes
relevant in heme cancers for diagnostic evaluation, prognosis, risk
stratification, and therapy guidance.
- 302 genes by DNA sequencing
- 302 genes for
- 23 genes for
copy number variants (CNVs)
- 184 genes by RNA sequencing
- both known and
Neo Comprehensive – Heme Cancers is the largest and most
comprehensive NGS panel for heme cancer assessment at NeoGenomics. It is
aligned with the latest guidelines, including the WHO 5th Edition
Classification, covering both myeloid and lymphoid neoplasms.
Some basic test details include:
- Specimen Requirements: bone marrow (2-3 mL), peripheral blood (3-5 mL), or FFPE
tissue (paraffin block)
- Turnaround Time (TAT): 14 days
- CPT Code*: 81455 (MolDx CPT Code: 81479)
- NYS Approval? Yes
Note: FLT3 by PCR (via
FLT3 Mutation Analysis) is available as an optional add-on, by Client-Bill
only, for faster FLT3 results (5-day TAT) for the purpose of prompt therapy
Important! The Neo Comprehensive
– Heme Cancers assay will immediately replace the NeoTYPE®
Discovery Profile for Hematologic Cancers (aka NeoTYPE Discovery Heme).
- Orders of the NeoTYPE profile will be automatically
converted to the new Neo Comprehensive assay.
- Pricing will remain the same.
For more info, please contact your local NeoGenomics
Territory Business Manager or visit the test page here.
*The CPT codes provided with our test descriptions are based
on AMA guidelines and are for informational purposes only. Correct CPT coding
is the sole responsibility of the billing party. Please direct any questions
regarding coding to the payor being billed.
Monday, October 2nd, we will be upgrading our existing Halo AI
Image Analysis Software for breast cancer markers and MMR panel.
- Validation of the HER2 membrane algorithm using Roche’s
updated HER2 protocol, a nuclear breast algorithm for ER, PR and AR, a
nuclear breast algorithm with nuclear segmenter for Ki67, as well as an
additional algorithm for our MMR panel.
- This upgrade will also include the ability to perform
analysis using 40X images, enhancements in Virtual Microscope viewer,
and changes to the tumor detection filter.
- Each algorithm has been validated in accordance with CAP
guidelines for validating Whole slide Imaging and for Quantitative Image
Analysis of HER2 IHC for Breast Cancer. Inter-laboratory and
inter-observer concordance were shown for IHC staining and Image
analysis performed at NeoGenomics laboratories in Aliso Viejo, CA,
Houston, TX and Fort Myers, FL.
Update: An updated Image
Analysis User Guide and recorded training are now available! Please review
the training in NeoUniversity™ here.
The Image Analysis User Guide is located along with the NeoUniveristy™
training as well as in NeoLINK under the ‘Documentation’ section. For any
immediate questions, please contact your local Sales Consultant or Client
Services at 1-866-776-5907, option 3.
New versions of all Heme requisition forms are now
available for download on Neo website
and for orders with Client Services team.
- Hematopathology Requisition – version 081023
- Oncology Office Hematology Requisition – version 081023
- New York State Hematopathology Requisition – version 080923
- New York State Oncology Office Hematology Requisition –
The below molecular tests are now discontinued.
Replacement options have been listed, if available, for your reference.
HER2 Colorectal IHC and FISH testing is now discontinued.
This discontinuation was due to a lack of consensus scoring for HER2 in
colorectal carcinoma using the HERACLES trial and no scoring recommendation
yet published by CAP/ASCO.
- Clients that want to test HER2 on Colorectal samples
should now order HER2 (Other) with Gastric Scoring for IHC
- The NeoTYPE®
Colorectal Tumor Profile and NeoTYPE®
GI Predictive Profile, both of which contained HER2 Colorectal
testing, now have HER2 (Other) with Gastric Scoring testing as the
- Important: This update is available in Online Orders and Interfaced
Orders. Test Requisitions will trail in being updated until the next
revision is available with an approximate October timeframe. As a
Colorectal orders that come in on test requisitions will automatically
be converted to HER2 (Other) with Gastric Scoring.
Interface and online ordering clients now have the
ability to easily order Neo Comprehensive™ – Solid Tumor as a
reflex option for their CancerTYPE® ID test.
When CancerTYPE ID® and NeoTYPE® Cancer Profiles are
ordered together, the NeoTYPE® profile performed will be based on the
CancerTYPE ID® result as shown on the CTID
ordering page. If Neo
Comprehensive – Solid Tumor is the preferred and ordered test, Neo
Comprehensive – Solid Tumor will be performed instead of a NeoTYPE®
profile (for non-New York). In addition, PD-L1 by IHC can be added-on to any
NeoTYPE profile (if not already included in profile) or Neo Comprehensive –
Solid Tumor. This expanded offering affords the opportunity for DNA and RNA
analysis to be performed for any sample through the Neo Comprehensive – Solid
Tumor panel of 517 genes plus TMB and MSI analysis.
For a complete list of interface-related test changes
that occurred on Monday September 11, click here
for a downloadable document to view the impacted interface test codes.